BLS Pharmaceuticals Limited

As of June 30, 2026, BLS Pharmaceuticals Limited has 229.98M shares outstanding.

As of June 30, 2026, BLS Pharmaceuticals Limited maintains a current ratio of 2.90, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 27.13, indicating elevated leverage, while an interest coverage ratio of 37.37 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BLS Pharmaceuticals Limited recorded an income tax benefit of -145,089.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 9.18M, leaving 9.33M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, BLS Pharmaceuticals Limited generated 44.92M in revenue and converted that into 9.33M in net income, yielding earnings per share of 0.04. EBITDA reached 10.41M, while operating income came in at 9.57M.

As of June 30, 2026, BLS Pharmaceuticals Limited holds 8.05M in cash and equivalents against 5.11M in total debt, resulting in a net debt position of -6.22M. Total book value stands at 18.83M, with working capital of 16.35M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, BLS Pharmaceuticals Limited posted a gross margin of 56.04, reflecting its pricing power and cost economics. The operating margin of 21.31 and net profit margin of 20.76 provide insight into operational efficiency.

BLS Pharmaceuticals Limited's most recent stock split took place on June 24, 2026 with a 10:1 split ratio.